SPARC investigational drug shows promise in phase 3 trial for treating inflammation, pain related to ocular surgery

The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.

Published On 2020-10-15 07:00 GMT   |   Update On 2020-10-15 07:27 GMT

New Delhi: Sun Pharma Advanced Research Company (SPARC) on Wednesday said it has received positive top-line results from phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. SPARC said its investigational drug met pre-specified primary and secondary endpoints.

"SPARC reported positive top-line results from its phase 3 trial for its investigational drug, SDN-037, for the treatment of inflammation and pain associated with ocular surgery. The trial met its pre-specified primary and secondary objectives," the company said in a regulatory filing.
The objective of the trial was to assess the efficacy and safety of SDN-037 in clearing the inflammation and pain, the company added.
Shares of SPARC were trading 0.56 per cent higher at Rs 170.30 apiece on BSE.



Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News